Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trametinib and Erlotinib in EGFR-Mutant Lung Adenocarcinoma
NCT03076164Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2017
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of trametinib in lung adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2017; status: completed.
02
Drugs
trametinib
03
Conditions
lung adenocarcinoma
Beyond the preview
Go deeper on NCT03076164.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03076164.